CpG island methylator phenotype (CIMP), in which multiple genes concordantly methylated, has been demonstrated to be associated with progression, recurrence, as well as overall survival in some types of cancer.

We examined the promoter methylation status of seven genes including P16, CDH1, GSTP1, DAPK, XAF1, SOCS1 and SYK in 65 cases of HCC treated with LT by methylation-specific PCR. CIMP+ was defined as having three or more genes that are concordantly methylated. The relationship between CIMP status and clinicopathological parameters, as well as tumor recurrence was further analyzed.

CIMP+ was more frequent in HCC with AFP [more than] 400 ng/ml than those with AFP [less than or equal to] 400 ng/ml (P=0.017). In addition, patients with CIMP+ were prone to have multiple tumor numbers than those with CIMP- (P=0.007). Patients with CIMP+ tumors had significantly worse recurrence-free survival (RFS) than patients with CIMP- tumors by Kaplan-Meier estimates (P= 0.004). Multivariate analysis also revealed that CIMP status might be a novel independent prognostic factor of RFS for HCC patients treated with LT (HR: 3.581; 95% CI: 1.473-8.710, P=0.005).

Our results suggested that CIMP could serve as a new prognostic biomarker to predict the risk of tumor recurrence in HCC after transplantation.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production